Professor Gina Brown MBBS MD MRCP FRCR FASCRS (Hon)

Prof Gina Brown 2014 photo

Professor of Gastrointestinal Cancer Imaging, Imperial College London

email: gina.brown@imperial.ac.uk

http://www.slideshare.net/GinaBrown3/presentations

http://scholar.google.com/citations?user=BwinzQIAAAAJ&hl=en

Professor  Gina Brown graduated from King’s College Hospital School of Medicine, London in 1988 and is Professsor of Gastrointestinal Cancer Imaging and Consultant Radiologist at Imperial College.  She has over 150 peer reviewed  publications, and has been the principal supervisor to  more than 10 successfully  awarded  higher degrees in colon and rectal cancer.  She had the title of Professor of Gastrointestinal Cancer Imaging conferred on her by Imperial College London in August 2014.

As the Radiology Faculty lead for the NHS National TME development programme (2003-2006)  and the National cancer action team Low Rectal Cancer Programme (2011-2013), she has been responsible for the training and roll-out of high quality rectal cancer MRI staging to over 180 multidisciplinary colorectal teams through  specialist workshops which have also been run successfully overseas.

She pioneered the investigation of imaging prognostic factors such as MRI prediction of CRM status, assessing response to treatment, assessment of nodes , extramural vascular invasion in colon and rectal cancer and implications for patient outcomes. This led to identification of key imaging predictors of patients at risk of developing local recurrence and metastatic disease now being targeted for treatment in larger phase II/III trials.  Professor Brown developed staging criteria in colon and rectal cancer and standards for reporting now adopted globally. She initiated and developed the UK  Deferral of Surgery trial protocol for rectal cancer patients in response to patients’ desires to avoid permanent stoma and defined the post radiotherapy MRI criteria to identify complete responders eligible for avoidance of surgery  now being tested in the prospective randomised clinical trial, TRIGGER.